Kim J. Hasenkrug, Ph.D.

Senior Investigator

Retroviral Immunology Section

NIAID/DIR

Building 3, Room 3219
903 South 4th Street
Hamilton, MT 59840

406-363-9310

khasenkrug@niaid.nih.gov

Research Topics

Our research is aimed at understanding host responses to retroviral infections. We use mice infected with Friend murine leukemia virus as a model to study basic immunology. A special interest is in chronic infections, including how chronic infections are established and maintained and developing strategies to prevent and treat them. Using this model, we discovered that viruses can subvert the suppressive nature of regulatory T cells to evade immunological destruction by CD8+ T cells. We also use “humanized” mice, mice that contain human immune systems, as a model to study immune responses to HIV infection and to help us determine basic mechanisms of vaccine protection against acute and chronic retroviral infections. The goal of these studies is to develop new ideas for HIV vaccines and therapies.

 

Scanning electron micrograph of a CD4+CD25+ regulatory T cell isolated from a mouse spleen. Cells such as these protect from autoimmune diseases, but they can also suppress virus-specific immunity and thereby lead to chronic infections.

Biography

Dr. Hasenkrug received his Ph.D. in cell biology from the Albert Einstein College of Medicine in 1991 and conducted his postdoctoral research in the laboratory of Dr. Bruce Chesebro at the Rocky Mountain Laboratories. In 1998, he established an independent laboratory to study retroviral immunology and mechanisms of vaccine protection. A special focus of his work has been the study of establishment and maintenance of chronic infections and virus escape. Dr. Hasenkrug serves as an affiliated associate professor at Montana State University and the University of Montana and as a scientific advisor for the International AIDS Vaccine Initiative.

Editorial Boards

  • PLoS One
  • Virology

Selected Publications

  1. Moore TC, Gonzaga LM, Mather JM, Messer RJ, Hasenkrug KJ. B Cell Requirement for Robust Regulatory T Cell Responses to Friend Retrovirus Infection. MBio. 2017;8(4).

  2. Joedicke JJ, Myers L, Carmody AB, Messer RJ, Wajant H, Lang KS, Lang PA, Mak TW, Hasenkrug KJ, Dittmer U. Activated CD8+ T cells induce expansion of Vβ5+ regulatory T cells via TNFR2 signaling. J Immunol. 2014;193(6):2952-60.

  3. Harper MS, Guo K, Gibbert K, Lee EJ, Dillon SM, Barrett BS, McCarter MD, Hasenkrug KJ, Dittmer U, Wilson CC, Santiago ML. Interferon-α Subtypes in an Ex Vivo Model of Acute HIV-1 Infection: Expression, Potency and Effector Mechanisms. PLoS Pathog. 2015;11(11):e1005254.

  4. Lavender KJ, Messer RJ, Race B, Hasenkrug KJ. Production of bone marrow, liver, thymus (BLT) humanized mice on the C57BL/6 Rag2(-/-)γc(-/-)CD47(-/-) background. J Immunol Methods. 2014;407:127-34.

  5. Lavender KJ, Gibbert K, Peterson KE, Van Dis E, Francois S, Woods T, Messer RJ, Gawanbacht A, Müller JA, Münch J, Phillips K, Race B, Harper MS, Guo K, Lee EJ, Trilling M, Hengel H, Piehler J, Verheyen J, Wilson CC, Santiago ML, Hasenkrug KJ, Dittmer U. Interferon Alpha Subtype-Specific Suppression of HIV-1 Infection In Vivo. J Virol. 2016;90(13):6001-13.


This page was last updated on February 9th, 2017